Hui‐Ling Zhen

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque et al. · The Lancet Oncology · 2020 · 1.5K citations · Full text

Gastrointestinal Oncology, Medicine, Hepatobiliary Tumor +11

Clinicogenomic Analysis of <i>FGFR2</i> -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

Ian M. Silverman, Antoine Hollebecque, Luc Friboulet et al. · Cancer Discovery · 2020 · 269 citations · Full text

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements

Tanios Bekaii‐Saab, Juan W. Valle, Eric Van Cutsem et al. · Future Oncology · 2020 · 159 citations · Full text

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Srđan Verstovšek, A. M. Vannucchi, Tamás Masszi et al. · Haematologica · 2016 · 156 citations · Full text

Hematological Malignancy, Polycythemia Vera, Urology +15

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko et al. · Nature · 2022 · 124 citations · Full text